

Original Research Article

Diagnosis of anti-citrullinated protein antibody negative rheumatoid arthritis depending on pathology associated with clinical phenotypes

ABSTRACT

Objectives: This study was done to assess the role of synovial tissue analysis in rheumatoid arthritis (RA) patients.

Methods: All data were recorded at baseline. All patients underwent clinical, radiologic, serologic, and histological assessments before treatment. Patients were divided into anti-citrullinated protein antibody (anti-CCP) positive and anti-CCP-negative and were compared according to different disease aspects. Correlations between clinical, laboratory, imaging, histological, and pathophysiological data were done for all patients.

Results: There were no statistically significant differences in synovial cell infiltrates according to the serology.

Conclusion: Both study groups had similar synovial cell infiltrates.

Keywords: arthritis; rheumatoid; synovial tissue; synovitis

Comment [SB[M1]: Mention the study design and sample size in the abstract too. Conclusion can be a little more descriptive. Results should include relevant statistics here, such as response rates, P-values or Confidence Intervals.

UNDER PEER REVIEW

1 **1. INTRODUCTION** 59
2
3 Increasing evidence suggests that anti-CCP
4 negative rheumatoid arthritis (RA) remains
5 entity distinct from that of ACPA+ disease with a
6 highly variable disease course [1, 2, 3]. This
7 translates to significant challenges in disease
8 management including definitive early diagnosis
9 remains uncertain, adversely affect outcomes in
10 part contributed by the challenges arising from
11 finding an early optimal therapy [4, 5, 6, 7, 8].
12 Thus, biomarkers capable of refining diagnosis
13 improving on current classification criteria early
14 the disease course and moreover predicting
15 outcome and treatment response for patients with
16 anti-CCP -ve RA are urgently needed in order to
17 both reduce morbidity and target biologic therapies
18 according to likelihood of response and/or
19 prognosis [9, 10, 11, 12] defined by specific
20 synovial cellular and molecular signatures and
21 moreover predict therapeutic response to disease
22 modifying therapy and joint damage progression.
23 Importantly, these pathotypes have also been
24 described in late-stage disease (joint replacement
25 tissue) [13] indicating the potential for such
26 pathotypes may function as disease endotype
27 classifiers.
28
29 Secondly, we have demonstrated that synovial
30 pathobiological signatures can improve on current
31 clinical classification criteria of early inflammatory
32 arthritis (RA2010 ACR/EULAR, RA1987 and
33 undifferentiated subgroups) through segregating
34 patients according to synovial cellular/molecular
35 signatures and clinical outcome including
36 requirement for biologic therapy at 12 months.
37 From the same PEAC data set preliminary results
38 have also demonstrated that the synovial cell
39 infiltrate (B cells, T cells, macrophages, and
40 plasma cells) in anti-CCP-ve RA is significantly
41 different from anti-CCP +ve patients while more
42 like PsA suggesting shared pathophysiological
43 mechanisms between sero-ve arthropathies
44 anti-CCP -ve RA. This offers the opportunity to
45 define a new taxonomy of disease for patients with
46 anti-CCP -ve RA and through the identification of
47 specific pathways of inflammation may enable the
48 development of pathology-driven, rather than
49 clinical classification-driven treatment algorithms.
50 Though similar approaches have been tried in the
51 past, mainly by the Amsterdam group [14, 15] on a
52 smaller number of patients in whom synovial
53 tissues were available (n=69 in total) and the lack
54 of matched molecular analysis in that cohort makes
55 this proposal of critical relevance.
56
57 Therefore, the overall aim of this project is to
58 examine in early arthritis patients whether sero-

veRA can be refined at disease initiation according to pathophysiological signatures associated with clinical phenotype.

2. PATIENTS AND METHOD

2.1 Enrollment of the Patients

This study was done on 30 RA patients collected from outpatient clinics diagnosed according to the latest diagnostic criteria of RA [5]. The patients included in this study complained of persistent activity in one joint despite their adherence to treatment.

Written informed consent from all the patients was obtained and all our patients. The patient who was excluded from this study is any patients with bleeding tendencies who received local injections of corticosteroid in the selected joint for synovium analysis in the last 3 months.

2.2 Clinical classification of patients

All patients underwent detailed history taking, joint counting, assessment of disease activity using the degree of tenderness of the injected joint was assessed on a score (0–3). The degree of pain was evaluated by using the visual analog scale (VAS) for pain in the affected joints measured using a ten cm horizontal scale with 10 degrees [16], then clinical classification via EULAR/ACR criteria for RA by exclusion according to revised classification criteria published since the initiation of the study. These included CASPAR criteria for psoriatic arthritis, and ASAS criteria for spondylarthritis.

2.3 Histological classification.

Synovium samples will undergo immunohistochemical staining and patients will be classified according to synovial pathotype, degree of synovitis. Differences in the degree of immune cell infiltration/synovitis within each diagnostic subgroup will be evaluated to look for significant associations between clinical classification and synovial histology. In addition, RA patients cluster according to synovium immune cell infiltration and whether the specific histological classification is reflected in variation in clinical parameters such as autoantibody expression, inflammatory marker elevation, disease activity, and radiographic damage.

Comment [SB[M2]: E a little clear about scope and justification of the study.

Comment [SB[M3]: Mention the aim in the beginning after introduction.

Comment [SB[M4]: Ethical clearance?

Comment [SB[M5]: May be deleted.

Comment [SB[M6]: Kindly rephrase. Difficult to understand, what the author means. Maybe write in points.

Comment [SB[M7]: Write the full form at least once in the whole manuscript

Comment [SB[M8]: Full form of the criteria?

111

112 2.4 Laboratory Tests

113 All the patients were assessed by complete blood count (CBC), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

116 2.5 Statistical Analysis of the Data

117 Data were analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). Qualitative data were described using the number and percent. Quantitative data were described using the mean and standard error of the mean. The probability value (p -value) ≤ 0.05 was considered statistically significant.

Comment [SB[M9]: percentage

124 3. RESULTS

125 The clinical characteristics of the patients were demonstrated in Table (1). There was a female predominance in our patients as 126 patients out of 179 were females. The mean age of the first group (anti-CCP negative) was 53.05 years old and the mean age of the second group (anti-CCP positive) was 50.43.

133 In the first group, the mean score of VAS pain was 53.03, VAS of global 64.6 and that of tenderness score was 40.33 while that of physician 59.6. In the second group, the mean score of VAS pain was 53.86, VAS of global 64.64 and that of tenderness score was 45.7, while that of physician 59.6. No statistically significant association was found between anti-CCP positivity and clinical disease activity.

142

143 The laboratory and histological data of the patients were demonstrated in Table (2). In the first group, the mean score of rheumatoid factor (RF) was 54.5, CRP was 17.4 and that of ESR was 39.8. In the second group, the mean score of rheumatoid factor (RF) was 162.7, CRP was 19.2 and that of ESR was 36.82. No statistically significant association was found between anti-CCP positivity and laboratory evaluation of the disease activity (CRP and ESR). Regarding the synovium cellular infiltration, there were no significant differences in the synovium infiltration between both study groups.

Table 1. Clinical data in the RA patients of the two studied groups

		ACPA – RA	ACPA + RA	P-value
Clinical	Age mean (SD)	53.05(14.45)	50.43(14.21)	0.290
	Female, n(%)	45(78.9%)	81(66.4%)	0.081
	Male, n(%)	12(21.1%)	41(33.6%)	0.113
	VAS tenderness	45.74(30.58)	40.33(30.18)	0.237
	VAS pain	53.86(28.17)	53.03(28.58)	0.903
	VAS global	63.95(23.04)	64.64(25.64)	0.575
	VAS physician	59.60(20.622)	59.53(23.76)	0.74
	TJC, n/28	13.09(7.58)	11.25(7.31)	0.164

VAS: Visual Analogue Scale

Table 2. Laboratory and histological data in the RA patients of the two studied groups

		ACPA – RA	ACPA + RA	P-value
Laboratory	ESR mm/h (median(IQ))	39.81(31.56)	36.82(26.26)	0.93
	CRP mg/dl (median(IQ))	17.45(25.33)	19.2(22.47)	0.52
	RF titre (IU) (median(IQ))	54.5(98.5)	162.7(180.2)	<0.001**
Synovial tissue	Synovitis score (median(IQ))	3 (9)	4 (9)	0.37

CRP: C Reactive Protein, ESR: Erythrocyte Sedimentation Rate

4. DISCUSSION

Many studies have been conducted on the generation and pathogenesis of ACPAs (anticitrullinated protein antibodies). It is believed that accumulated citrullinated proteins trigger ACPA production, and the type of ACPA produced can vary depending on the antigens and antibody isotypes involved. The pathogenesis of ACPAs can be divided into two stages, with a marked increase in ACPA levels after the second hit. Furthermore, glycosylation of the antibodies can affect their stability and biological activity, thus enhancing the pathogenicity of ACPAs. Additionally, ACPAs are known to have direct or indirect participation in bone damage.

In a histological point of view, previous reports have supported the short-term anti-inflammatory effects, such as inhibition of synovial hyperplasia, reduction of intra-synovial citrullinated protein,

and inhibition of growth factor proliferation, in response to glucocorticoids. So, glucocorticoids can provide excellent short-term inflammatory control and analgesic while the latter represents mixed findings regarding the long-term effects of this intervention [17].

In our study, there was no significant difference in clinical assessment of our patients through VAS in both groups. These agreed with **Van Oosterhout et al** (2008) who found no statistically significant difference in ACPA-positive and ACPA-negative as regard age, sex, and disease duration, and most of the patients were females. [18]

Additionally, there was no significant difference in laboratory assessment of our patients through ESR, and CRP subsequently in both groups. Our results are agreed with **Burgers et al** (2017) found no significant differences in acute phase reactants. [19].

In our study of the synovium structure and its infiltration with inflammatory cells, there were no

significant differences in the synovium infiltration between both study groups which demonstrated that synovium that was analysed from both study groups. Gomez-Puerta et al (2013) was consistent with our findings of similarity in the cellular infiltrates' levels between ACPA positive and negative RA patients. As systemic and local inflammation was similar in the study groups, these findings support a similar synovial physiopathology.

This suggests that acute joint pain in RA patients with advanced joint deformities can be prevented successfully with early diagnosis and proper early management.[29]

To summarize, the importance of pathology in early diagnosis of RA is magnified and its role in proper management needs more studies. The limitation of this study was the short period, no follow-up evaluation and assessment of accuracy.

CONCLUSION

No statistically significant differences were found in synovial cell infiltrates according to the serology.

CONSENT

As per international standard and university standard, patient(s) written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

It is not applicable.

Comment [SB[M10]: Include under limitation.

Comment [SB[M11]: Conclusion should include your views why or what is the reason of your result and how it is beneficial.

Comment [SB[M12]: Mention the limitations

Comment [SB[M13]: Explain why?

REFERENCES

1. Ajeganova S, van der Helm-van Mil AH, Hafström I, Huizinga TW, Toes RE, Svensson B, van der Woude D. Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. *Ann Rheum Dis.* 2017 Apr;76(4):716-720.
2. Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, Uhlig T, Jonsson MK, van der Heijde D, Kvien TK, Haavardsholm EA; and the ARCTIC working group. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. *Ann Rheum Dis.* 2017 Feb;76(2):341-345.
3. Ajeganova, S. & Huizinga, T. W. J. *Nat. Rev.* Seronegative and seropositive RA: alike but different? *Rheumatol.* 11, 8–9 (2015);
4. Coates LC, Conaghan PG, Emery P, *et al.* Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. *Arthritis Rheum* 2012;64:3150–5.
5. de Hair MJ1, Lehmann KA, van de Sande MG, Maijer KI, Gerlag DM, Tak PP. The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria: is this still the same disease? *Arthritis Rheum.* 2012 Feb;64(2):389-93.
6. Sakellariou G, Scirè CA, Zambon A, Caporali R, Montecucco C. Performance of the 2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta-analysis. *PLoS One.* 2013;8(2):e56528.
7. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. *Am J Med.* 2001 Oct 15;111(6):446-51.
8. Finckh AI, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. *Arthritis Rheum.* 2006 Dec 15;55(6):864-72.
9. Nakken B, Papp G, Bosnes V, Zeher M, Nagy G, Szodoray P. Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives. *Immunol Lett.* 2017 Sep; 189:13-18. doi: 10.1016/j.imlet.2017.05.010. Epub 2017 May 16.
10. Dekkers JI, Toes RE, Huizinga TW, van der Woude D. The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. *Curr Opin Rheumatol.* 2016 May;28(3):275-81.
11. Jutley G, Raza K, Buckley CD. New pathogenic insights into rheumatoid arthritis. Jutley G, Raza K, Buckley CD. New pathogenic insights into rheumatoid arthritis. *Curr Opin Rheumatol.* 2015 May;27(3):249-55.
12. Pitzalis C, Kelly S, Humby F. *Curr Opin Rheumatol.* 2013 May;25(3):334-44. New learnings on the pathophysiology of RA from synovial biopsies.
14. Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S, Song A, Musselman D, Klearman M, Gabay C, Kavanaugh A, Endres J, Fox DA, Martin F, Townsend MJ. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. *Arthritis Res Ther.* 2014;16(2):R90.
15. Marleen G. H. van de Sande, Maria J. H. de Hair, Yvonne Schuller, Gijs P. M. van de Sande, Carla A. Wijbrandts, Huib J. Dinant, Danielle M. Gerlag, Paul P. Tak. The Features of the Synovium in Early Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria. *PLoS ONE* | www.plosone.org May 2012 | Volume 7 | Issue 5 | e36668
16. Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. *J Am Acad Orthop Surg Glob Res Rev.* 2018 Mar 23;2(3):e088.
17. Makrygiannakis D, Revu S, Engström M, *et al.* Local administration of glucocorticoids

Comment [SB[M14]: Very old reference. May be replaced with a relatively newer reference?

- decreases synovial citrullination in rheumatoid arthritis. *Arthritis Res Ther.* 2012;14:R20.
18. Burgers LE, Steenbergen HW Van, Brinck RM, Huizinga TWJ, Mil AHMVDH. Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. 2017;1751-4.
 19. Van Oosterhout M, Bajema I, Levarht EWN, Toes REM, Huizinga TWJ, Van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. *Arthritis Rheum.* 2008;58(1):53-60.
 20. Gómez-Puerta JA, Celis R, Hernández MV, Ruiz-Esquide V, Ramírez J, Haro I, Cañete JD, Sanmartí R. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients. *Arthritis Res Ther.* 2013 Nov 7;15(6):R182.
-

UNDER PEER REVIEW